Strategies for patients who discontinue Prolia® and are otherwise naïve
ESCEO 2017: Prof. Serge Ferrari
Treatment strategies for prior bisphosphonate patients who discontinue Prolia®
ESCEO 2017: Juliet Compston
Call for Action on addressing the crisis in the treatment of osteoporosis
External expert presentations
Discontinuation of Prolia® therapy for osteoporosis: A systematic review and position statement by ECTS
The European Calcified Tissue Society (ECTS) formed a working group to perform a systematic review of existing literature on the effects of Prolia® discontinuation, and provide advice on the management of osteoporosis, a chronic disease that requires long-term treatment.
The review highlights the evidence based around Prolia® discontinuation, the need for re-evaluation of patients after 5 years of treatment, and that treatment should not be stopped without considering an alternative anti-resorptive treatment.
Results from the Phase III randomized FREEDOM trial and open-label extension
In the FREEDOM trial and its open-label extension, treatment with Prolia® for up to10 years was associated with consistently low rates of adverse events, a sustained low incidence of fractures and a continued increase in BMD without therapeutic plateau.
The authors concluded that long-term treatment with Prolia® is effective, well tolerated and has a favourable benefit-risk profile.
ASBMR: American Society for Bone and Mineral Research; BMD: bone mineral density; ECTS: European Calcified Tissue Society; ESCEO: European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; EULAR: European League Against Rheumatism; FFN: Fragility Fracture Network.